Grapefruit juice-drug interactions.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  1998-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1046/J.1365-2125.1998.00764.XPMID 9723817PMCID PMC1873672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine — and its potential clinical relevance

  2004cited by this paper
• Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects

  2004cited by this paper
• Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine.

  2000cited by this paper
• Grapefruit juice—felodipine interaction: Effect of naringin and 6′,7′‐dihydroxybergamottin in humans

  1998cited by this paper
• Grapefruit juice increases oral nimodipine bioavailability.

  1998cited by this paper
• The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice

  1997cited by this paper
• Drug interactions with grapefruit: Whose responsibility is it to warn the public?

  1997cited by this paper
• Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

  1997cited by this paper
• OF ENHANCED ORAL AVAILABILITY OF CYP 3 A 4 SUBSTRATES BY GRAPEFRUIT CONSTITUENTS Decreased enterocyte CYP 3 A 4 concentration and mechanism-based inactivation by furanocoumarins

  1997cited by this paper
• Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men

  1997cited by this paper
• Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction.

  1997cited by this paper
• Combined use of astemizole and ketoconazole resulting in torsade de pointes.

  1997cited by this paper
• Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins.

  1997cited by this paper
• Grapefruit juice—terfenadine single‐dose interaction: Magnitude, mechanism, and relevance

  1997cited by this paper
• Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram

  1996cited by this paper
• Can grapefruit juice influence ethinylestradiol bioavailability?

  1996cited by this paper
• First‐pass metabolism of midazolam by the human intestine

  1996cited by this paper
• Grapefruit Juice Alters the Systemic Bioavailability and Cardiac Repolarization of Terfenadine in Poor Metabolizers of Terfenadine

  1996cited by this paper
• Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?

  1996cited by this paper
• Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease.

  1996cited by this paper
• Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

  1996cited by this paper
• Erythromycin‐felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice

  1996cited by this paper
• Cisapride

  1996cited by this paper
• Effect of Grapefruit Juice on the Pharmacokinetics and Pharmacodynamics of Quinidine in Healthy Volunteers

  1996cited by this paper
• Cisapride and fatal arrhythmia.

  1996cited by this paper
• Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.

  1996cited by this paper
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996cited by this paper
• Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers

  1996cited by this paper
• Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice.

  1996cited by this paper
• Effect of grapefruit juice on blood cyclosporin concentration.

  1995cited by this paper
• Grapefruit juice and saquinavir.

  1995cited by this paper
• Interaction between grapefruit juice and midazolam in humans

  1995cited by this paper
• Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation?

  1995cited by this paper
• Grapefruit juice and saquinavir.

  1995cited by this paper
• Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice

  1995cited by this paper
• Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation.

  1995cited by this paper
• Disposition of intravenous and oral cyclosporine after administration with grapefruit juice

  1995cited by this paper
• Effect of grapefruit juice on blood cyclosporin concentration.

  1995cited by this paper
• Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.

  1995cited by this paper
• The fate of naringin in humans: A key to grapefruit juice‐drug interactions?

  1995cited by this paper
• [Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].

  1995cited by this paper
• Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor.

  1995cited by this paper
• Factors affecting the absolute bioavailability of nifedipine.

  1995cited by this paper
• The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients

  1995cited by this paper
• Lacking effect of grapefruit juice on theophylline pharmacokinetics.

  1995cited by this paper
• Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers

  1995cited by this paper
• Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma.

  1995cited by this paper
• Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.

  1995cited by this paper
• Nifedipine in ischemic heart disease.

  1995cited by this paper
• Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function.

  1995cited by this paper
• Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects.

  1994cited by this paper
• Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.

  1994cited by this paper
• Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine.

  1994cited by this paper
• Torsades de pointes induced by erythromycin and terfenadine.

  1994cited by this paper
• Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity.

  1994cited by this paper
• Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

  1994cited by this paper
• Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women.

  1994cited by this paper
• Torsade de pointes induced by terfenadine in a patient with long QT syndrome.

  1994cited by this paper
• Grapefruit Juice and Drugs

  1994cited by this paper
• Trough concentrations of cyclosporine in blood following administration with grapefruit juice.

  1993cited by this paper
• Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.

  1993cited by this paper
• Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.

  1993cited by this paper
• Mechanism of the cardiotoxic actions of terfenadine.

  1993cited by this paper
• Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation.

  1993cited by this paper
• Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics

  1993cited by this paper
• Itraconazole Affects Single‐Dose Terfenadine Pharmacokinetics and Cardiac Repolarization Pharmacodynamics

  1993cited by this paper
• Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice.

  1993cited by this paper
• Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart.

  1993cited by this paper
• Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine.

  1993cited by this paper
• Grapefruit juice–felodipine interaction: Mechanism, predictability, and effect of naringin

  1993cited by this paper
• Torsades de pointes after terfenadine-itraconazole interaction.

  1993cited by this paper
• Grapefruit juice: a possible source of variability in blood concentration of cyclosporin A.

  1993cited by this paper
• Torsades de Pointes after treatment with terfenadine and ketoconazole.

  1992cited by this paper
• Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice.

  1992cited by this paper
• Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

  1992cited by this paper
• Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin

  1992cited by this paper
• Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans

  1991cited by this paper
• Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes.

  1991cited by this paper
• Interaction of citrus juices with felodipine and nifedipine.

  1991cited by this paper
• Torsades de pointes occurring in association with terfenadine use.

  1991cited by this paper
• A population study of the pharmacokinetics of felodipine.

  1991cited by this paper
• Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

  1991cited by this paper
• Rhabdomyolysis associated with lovastatin and erythromycin use.

  1991cited by this paper
• Rhabdomyolysis and simvastatin.

  1991cited by this paper
• Proischemic complications of dihydropyridine calcium channel blockers.

  1991cited by this paper
• First-pass metabolism of cyclosporin by the gut.

  1991cited by this paper
• In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids.

  1990cited by this paper
• Pharmacokinetics and biotransformation of 1,4-dihydropyridine calcium antagonists

  1990cited by this paper
• Torsades de pointes occurring in association with terfenadine use.

  1990cited by this paper
• Stereoselective inhibition of thromboxane-induced coronary vasoconstriction by 1,4-dihydropyridine calcium channel antagonists.

  1990cited by this paper
• Plasma Concentration—Effect Relationships of Intravenous and Extended‐Release Oral Felodipine in Hypertensive Patients

  1990cited by this paper
• Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues.

  1990cited by this paper
• Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

  1989cited by this paper
• Ethanol enhances the hemodynamic effects of felodipine.

  1989cited by this paper
• Cardiotoxic effect with convulsions in terfenadine overdose.

  1989cited by this paper
• Electrophysiologic Effects of Dextro‐ and Levo‐Verapamil on Sinus Node and AV Node Function in Humans

  1988cited by this paper
• Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.

  1988cited by this paper
• Pharmacokinetics of Calcium Antagonists Under Development

  1988cited by this paper
• Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.

  1988cited by this paper
• Astemizole: A Long-Acting, Nonsedating Antihistamine

  1987cited by this paper

• Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended‐Release Tacrolimus (LCPT) Using Grapefruit Juice

  2026cites this paper
• Machine learning models for drug-drug interaction prediction from computational discovery to clinical application

  2026cites this paper
• Fruit Bagging Enhances Peel Color and Affects Fruit Quality of Citrus Under Protected Screen-grown Grapefruit-like Hybrid ‘914’

  2025cites this paper
• QM/MM Study of the Metabolic Oxidation of 6′,7′-Dihydroxybergamottin Catalyzed by Human CYP3A4: Preferential Formation of the γ-Ketoenal Product in Mechanism-Based Inactivation

  2025cites this paper
• Herb-Drug Interactions: A Critical Exploration in Modern Healthcare Practices

  2025cites this paper
• Evaluation of Solubility-Limited Absorption as a Surrogate to Predicting Positive Food Effect of BCS II/IV Drugs

  2025cites this paper
• Bergamottin, A Natural Bioactive Compound, Inhibits Dabie Bandavirus Infection In Vitro and In Vivo

  2025cites this paper
• An Update of Clinically Significant Grapefruit Juice-Drug Interactions

  2025cites this paper
• A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications.

  2025cites this paper
• Food Additives Inhibit Intestinal Drug Transporters but Have Limited Effect on In Vitro Drug Permeability

  2025cites this paper
• Clinical Pharmacology of Felodipine

  2025cites this paper
• Optimizing endectocide and ectocide compound evaluation in Anopheles malaria vectors

  2025cites this paper
• Naringin: A flavanone with a multifaceted target against sepsis-associated organ injuries.

  2024cites this paper
• Combined effects of naringin and doxorubicin on the JAK/STAT signaling pathway reduce the development and spread of breast cancer cells

  2024cites this paper
• Knowledge of Food–Drug Interactions among Medical University Students

  2024cites this paper
• Physiochemical characterization and pharmacokinetic assessment of Bergamottin solid lipid nanoparticles

  2024cites this paper
• Pharmacokinetics of Dasatinib in Rats: a Potential Food–Drug Interaction with Naringenin

  2024cites this paper
• Comparing the oxidative functions of neutrophil myeloperoxidase and cytochrome P450 enzymes in drug metabolism.

  2024cites this paper
• Interactions between medicinal plants used in the treatment of heart diseases and antihypertensive medication

  2024cites this paper
• Extraction, Characterization, and Biological Activity of Volatile and Non-volatile Components of Grapefruit

  2024cites this paper
• The Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond

  2024cites this paper
• Awareness and knowledge of drug-drug and food-drug interactions among adults in Poland – a questionnaire-based survey

  2024cites this paper
• Possible Side Effects of Polyphenols and Their Interactions with Medicines

  2023cites this paper
• Quantitative Prediction of Intestinal Absorption of Drugs from In Vitro Study: Utilization of Differentiated Intestinal Epithelial Cells Derived from Intestinal Stem Cells at Crypts

  2023cites this paper
• Effect of hydroxylated and methylated flavonoids on cytochrome P450 activity in porcine intestinal epithelial cells.

  2023cites this paper
• Overview of Adductomics in Toxicology

  2023cites this paper
• Pomelo juice–Drug interactions: A word of caution

  2023cites this paper
• Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.

  2023cites this paper
• The Hazard Index at thirty-seven: new science new insights

  2023cites this paper
• Phytotherapy and Drugs: Can Their Interactions Increase Side Effects in Cancer Patients?

  2023cites this paper
• Evaluation of metabolism and cytochrome P450 mediated interaction liabilities of naringenin

  2023cites this paper
• Evaluation and prediction of oral drug absorption and bioequivalence with food-druginteraction.

  2023cites this paper
• Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance

  2023influential citation
• Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom

  2023cites this paper
• 2,3,5,4'-Tetrahydroxy stilbene-2-Ο-β-D-glucoside, a mechanism-based inactivator of CYP2C19 and CYP3A4, potentiates hepatic protein adduction and hepatotoxicity induced by emodin in vivo.

  2022cites this paper
• A machine learning liver-on-a-chip system for safer drug formulation

  2022cites this paper
• What Is Known about Midazolam? A Bibliometric Approach of the Literature

  2022influential citation
• Drug Interactions with Food and Beverages

  2022cites this paper
• Pharmacokinetic profiles, cytotoxicity, and redox metabolism of free and nanoencapsulated curcumin

  2022cites this paper
• Impact of route-dependent phase-II gut metabolism and enterohepatic circulation on the bioavailability and systemic disposition of resveratrol in rats and humans: A comprehensive whole body physiologically-based pharmacokinetic modeling.

  2022cites this paper
• The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences.

  2022cites this paper
• Drug-drug interactions

  2022cites this paper
• Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review

  2022cites this paper
• Evidence of Biological Mechanisms and Health Predictions: An Insight into Clinical Reasoning

  2022cites this paper
• Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial

  2022cites this paper
• Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling

  2021cites this paper
• Naringenin Release to Biomembrane Models by Incorporation into Nanoparticles. Experimental Evidence Using Differential Scanning Calorimetry

  2021cites this paper
• Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials.

  2021cites this paper
• Клинически значимые взаимодействия лекарственных средств с фруктовыми и ягодными соками

  2021influential citation
• Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy

  2021cites this paper
• Annual population fluctuations of Mediterranean fruit fly in the Eastern Mediterranean Region of Turkey; Problem of non-marketing fruit

  2021cites this paper
• Mechanistic study of bergamottin-induced inactivation of CYP2C9.

  2021cites this paper
• Quercetin for the Experimental Treatment of COVID-19

  2021cites this paper
• Effect of Vernonia Amygdalina Leaf on Cytochrome P450 2D6- and 3A4-Mediated Metabolism of Dextromethorphan in Healthy Nigerian Subjects

  2021cites this paper
• The Impact of Diet and Exercise on Drug Responses

  2021cites this paper
• Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats.

  2021cites this paper
• Modeling Pharmacokinetic Natural Product–Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach

  2021cites this paper
• An insight on the nature of biochemical interactions between glycyrrhizin, myricetin and CYP3A4 isoform.

  2021cites this paper
• Interactions between nutraceuticals/nutrients and nutrients and therapeutic drugs

  2021cites this paper
• Cannabidiol safety

  2021cites this paper
• Natural Products as Modulators of CES1 Activity

  2020cites this paper
• In Vitro Human Cell–Based Experimental Models for the Evaluation of Enteric Metabolism and Drug Interaction Potential of Drugs and Natural Products

  2020cites this paper
• Grapefruit juice enhances the systolic blood pressure‐lowering effects of dietary nitrate‐containing beetroot juice

  2020cites this paper
• Chimeric cytochrome P450 3A4 used for in vitro prediction of food–drug interactions

  2020cites this paper
• Prediction methods of drug-drug interactions of non-oral CYP3A4 substrates based on clinical interaction data after oral administrations - Validation with midazolam, alfentanil, and verapamil after intravenous administration and prediction for blonanserin transdermal patch.

  2020cites this paper
• Grapefruit

  2020cites this paper
• Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions — Minireview Natural Products as Modulators of CES1 Activity

  2020cites this paper
• Systematic Review of Voxelotor: A First‐in‐Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease

  2020cites this paper
• The role of biotransformation processes in mediating interactions between psychotropic drugs and natural products

  2020cites this paper
• The increasing challenge of the possible impact of ethnicity on psychopharmacology

  2020cites this paper
• Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study

  2020cites this paper
• Concurrent Short Term Administration of Artesunate and Methanol Extract of Ficus Platyphylla Has No HepatoRenal Consequences in Rats

  2020cites this paper
• Xenobiotic Metabolic Enzymes: Bioactivation and Antioxidant Defense

  2020cites this paper
• Application of Cryopreserved Human Intestinal Mucosa and Cryopreserved Human Enterocytes in the Evaluation of Herb-Drug Interactions: Evaluation of CYP3A Inhibitory Potential of Grapefruit Juice and Commercial Formulations of Twenty-Nine Herbal Supplements

  2020cites this paper
• Synthesis of Spin-Labelled Bergamottin: A Potent CYP3A4 Inhibitor with Antiproliferative Activity

  2020cites this paper
• Hepatitis

  2020cites this paper
• Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature.

  2020cites this paper
• Convergent evolution leading to the appearance of furanocoumarins in citrus plants.

  2020cites this paper
• Pharmaconutrigenetics: The Impact of Genetics on Nutrient–Drug Interactions

  2020cites this paper
• Are reports of reduced field efficacy of diphacinone and chlorophacinone in California ground squirrels (Otospermophilus beecheyi) due to elevated rodenticide metabolism?

  2020cites this paper
• Development and Validation of Montelukast with Grape/Licorice Juices and its Application to Pharmacokinetic Studies by LC/MS

  2020cites this paper
• Pharmaceutical Excipients and Drug Metabolism: A Mini-Review

  2020cites this paper
• Food–Drug Interactions with Fruit Juices

  2020cites this paper
• COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

  2020cites this paper
• Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders

  2020cites this paper
• Photosensitizing Furocoumarins: Content in Plant Matrices and Kinetics of Supercritical Carbon Dioxide Extraction

  2020cites this paper
• Polyphenols, the new frontiers of prebiotics.

  2020cites this paper
• Dietary Inducers of Detoxification Enzymes

  2020cites this paper
• An Overview of Drug Interactions With Grapefruit Juice

  2020cites this paper
• Review on Preclinical and Clinical Evidence of Food (Beverages, Fruits and Vegetables) and Drug Interactions: Mechanism and Safety

  2020cites this paper
• The pharmacologic management of multiple myeloma in older adults

  2019cites this paper
• Preoperative Evaluation, Premedication, and Induction of Anesthesia

  2019cites this paper
• Botanical Sources, Chemistry, Analysis, and Biological Activity of Furanocoumarins of Pharmaceutical Interest

  2019cites this paper
• In-vitro assessment of CYP 3 A 4 and CYP 2 C 9 inhibition potential of Lupeol using human liver microsomes

  2019cites this paper
• Pharmaceutical perspective on the translational hurdles of phytoconstituents and strategies to overcome

  2019cites this paper
• Evaluation of Drug-diet interaction between Psidium guajava (Guava) fruit and Metoclopramide

  2019cites this paper
• Considerations for the Use of Polyphenols as Therapies in Neurodegenerative Diseases

  2019cites this paper
• The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group.

  2019cites this paper
• Impact of Subacute Exposure to T-2 Toxin and Zearalenone on the Pharmacokinetics of Midazolam as CYP3A Probe Drug in a Porcine Animal Model: A Pilot Study

  2019cites this paper
• Peppermint (Mentha piperita L.) extract effectively inhibits cytochrome P450 3A4 (CYP3A4) mRNA induction in rifampicin-treated HepG2 cells

  2019cites this paper